These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15850827)

  • 1. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.
    Wood A; Armour D
    Prog Med Chem; 2005; 43():239-71. PubMed ID: 15850827
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human.
    Napier C; Sale H; Mosley M; Rickett G; Dorr P; Mansfield R; Holbrook M
    Biochem Pharmacol; 2005 Dec; 71(1-2):163-72. PubMed ID: 16298345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.
    Lemoine RC; Petersen AC; Setti L; Baldinger T; Wanner J; Jekle A; Heilek G; deRosier A; Ji C; Rotstein DM
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1674-6. PubMed ID: 20137937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
    Meanwell NA; Kadow JF
    Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
    Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4633-7. PubMed ID: 16782336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans.
    Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5 pharmacology methodologies and associated applications.
    Mansfield R; Able S; Griffin P; Irvine B; James I; Macartney M; Miller K; Mills J; Napier C; Navratilova I; Perros M; Rickett G; Root H; van der Ryst E; Westby M; Dorr P
    Methods Enzymol; 2009; 460():17-55. PubMed ID: 19446719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H; Kokubo M; Hamano S; Hamanaka N; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
    J Med Chem; 2006 Jul; 49(14):4140-52. PubMed ID: 16821774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 10-Methoxydihydrofuscin, fuscinarin, and fuscin, novel antagonists of the human CCR5 receptor from Oidiodendron griseum.
    Yoganathan K; Rossant C; Ng S; Huang Y; Butler MS; Buss AD
    J Nat Prod; 2003 Aug; 66(8):1116-7. PubMed ID: 12932138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.
    Nishizawa R; Nishiyama T; Hisaichi K; Matsunaga N; Minamoto C; Habashita H; Takaoka Y; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2007 Feb; 17(3):727-31. PubMed ID: 17118654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.
    Dorn CP; Finke PE; Oates B; Budhu RJ; Mills SG; MacCoss M; Malkowitz L; Springer MS; Daugherty BL; Gould SL; DeMartino JA; Siciliano SJ; Carella A; Carver G; Holmes K; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller M; Schleif WA; Emini EA
    Bioorg Med Chem Lett; 2001 Jan; 11(2):259-64. PubMed ID: 11206473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
    J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The seventh transmembrane domain of cc chemokine receptor 5 is critical for MIP-1beta binding and receptor activation: role of MET 287.
    Youn BS; Yu KY; Alkhatib G; Kwon BS
    Biochem Biophys Res Commun; 2001 Mar; 281(3):627-33. PubMed ID: 11237703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV. One on one meets two.
    Wain-Hobson S
    Nature; 1996 Nov; 384(6605):117-8. PubMed ID: 8906782
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
    Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
    Curr Top Med Chem; 2008; 8(13):1140-51. PubMed ID: 18782009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.